The pharmacogenomics of depression: mapping the social and ethical impact

Journal of Public Mental Health

Volumn 4, Issue 3, 2005, Pages 33-41

  Barr, Michael ^a   Singh, Ilina ^a   Rose, Nikolas ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Antidepressant medication; Biomedical ethics; Depression; Genetic testing; Pharmacogeno mics

Indexed keywords

EID: 84992954193     PISSN: 17465729     EISSN: 20428731     Source Type: Journal    
DOI: 10.1108/17465729200500022     Document Type: Review

References (46)

1. BBC News Online (2005) GSK investors bring Paxil lawsuit. BBC News Online 14 April. Available at http://news.bbc.co.uk/1/hi/business/4443697.stm. (accessed 12 June 2005).
2. Bhopal R (2002) Revisiting race/ethnicity as a variable in health research. American Journal of Public Health 92 156-157.
3. Bhopal R, Donaldson L (1998) White, European, Western, Caucasian, or what? Inappropriate labelling in research on race, ethnicity, and health. American Journal of Public Health 88 1303-1307.
4. Bhopal R, Rankin J (1999) Concepts and terminology in ethnicity, race and health: be aware of the ongoing debate. British Dental Journal 186 483-484.
5. Bradby H (2003) Describing ethnicity in health research. Ethnicity & Health 8 5-13.
6. Bradstreet S, Norris R (eds) (2004) All you need to know? A Scottish survey of people's experience of psychiatric drugs. Edinburgh: Scottish Association for Mental Health.
7. Braun L (2002) Race, ethnicity, and health: can genetics explain disparities? Perspectives in Biology and Medicine 45 159-174.
8. Cooper RS, Freeman VL (1999) Limitations in the use of race in the study of disease causation. Journal of the National Medical Association 91 379-383.
9. Dequeker E, Cassiman JJ (2000) Genetic testing and quality control in diagnostic laboratories. Nature Genetics 25 259-260.
10. Dobson R (2003) Pharmaceutical industry is main influence in GP prescribing. British Medical Journal 326 301.
11. Elliot C, Chambers T (2004) Prozac as a way of life. Chapel Hill: University of North Carolina Press.
12. Hahn RA, Mulinare J, Teutsch SM (1992) Inconsistencies in coding of race and ethnicity between birth and death in United States infants: a new look at infant mortality, 1983 through 1985. Journal of the American Medical Association 267 259-263.
13. Haimes E, Whong-Barr M (2004) Levels and styles of participation in genetic databases: a case study of the North Cumbria genetics project. In: Tutton R, Corrigan O (eds) Donating and exploiting DNA: social and ethical aspects of public participation in genetic databases. London: Routledge.
14. Health Canada (2003) ICH topic E5 - Note for guidance on ethnic factors in the acceptability of foreign clinical data. Available at: http://www.hcsc.gc.ca/hpfb-dgpsa/tpd-dpt/e5_e.pdf. (accessed 15 June 2005).
15. Healy D (2004) Psychiatric drugs explained. 4th edition. London: Churchill Livingston.
16. Healy D (2002) The creation of psychopharmacology. Cambridge: Harvard University Press.
17. Hedgecoe A (2004) The politics of personalised medicine: pharmacogenetics in the clinic. Cambridge: Cambridge University Press.
18. House of Commons (2005) The influence of the pharmaceutical industry.
19. Health Committee fourth report of session 2004-2005 vol 1. London: The Stationery Office.
20. Kahn J (2004) How a drug becomes ‘ethnic’: law, commerce, and the production of racial categories in medicine. Yale Journal of Health Policy, Law, and Ethics IV 1-46.
21. Karp D (1997) Speaking of sadness: depression, disconnection, and the meanings of illness. Oxford University Press.
22. Kuivenhoven JA, Jukema JW, Zwinderman AH et al (1998) The role of a common variant of the cholesterol protein gene in the progression of coronary atherosclerosis. New England Journal of Medicine 338 86-93.
23. La Caze A (2005) Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems? Pharmacogenomics 23 445-447.
24. Lesch KP, Gutknecht L (2004) Focus on the 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenomics. International Journal of Neuropsychopharmacology 7 381-385.
25. Lindpaintner K (2002) The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nature Reviews 1 463-469.
26. Matsui K, Kita Y, Ueshima Y (2005) Informed consent, participation in, and withdrawal from a population based cohort study involving genetic analysis. Journal of Medical Ethics 31 385-392.
27. Medicines and Healthcare Products Regulatory Agency (MHRA) (2004) Selective serotonin reuptake inhibitor (SSRI) antidepressants: findings of the Committee on Safety of Medicines (CSM) working group. Annex a: prescribing trends of SSRIs and related antidepressants. London: MHRA.
28. Mental Health Foundation (2004) Minority ethnic groups and mental health. Available at: mentalhealth.org.uk/page.cfm?pagecode=PEISBE Mental Health Foundation (2005) Up and running? exercise therapy and the treatment of mild or moderate depression in primary care. London: MHF.
29. MIND (2004) Submission to the joint committee on the Mental Health Bill. Available at www.mind.org.uk (accessed 14 June 2005).
30. Morley K, Hall W (2004) Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. Journal of Molecular Medicine 82 21-30.
31. National Institute of Clinical Excellence (NICE) (2003) Depression: management of depression in primary and secondary care. Clinical guideline 23. London: National Institute of Clinical Excellence.
32. Nazroo JY (2003) The structuring of ethnic inequalities in health: economic position, racial discrimination, and racism. American Journal of Public Health 93 277-284.
33. Netzer C, Biller-Andorno N (2004) Pharmacogenomic testing: informed consent and the problem of secondary information. Bioethics 18 344-360.
34. Ng CH, Schweitzer I, Norman T et al (2004) The emerging role of pharmacogenetics: implications for clinical psychiatry. Australian and New Zealand Journal of Psychiatry 38 483-489.
35. Nuffield Council on Bioethics (Nuffield) (2003) Pharmacogenomics: ethical issues. London: Nuffield Council on Bioethics.
36. Phillips K, Van Bebber S (2004) A systematic review of costeffectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5 1139-1149.
37. Pound P, Britten N, Morgan M et al (2005) Resisting medicines: a synthesis of qualitative studies of medicine taking. Social Science and Medicine 61 133-155.
38. Pratt LA, Ford DE, Crum RM et al (1996) Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 94 3123-3129.
39. Rochon PA, Mashari A, Cohen A et al (2004) The inclusion of minority groups in clinical trials: problems of under representation and under reporting of data. Accountability in Research 11 215-223.
40. Rose N (2005a) Race and ethnicity in health genomics. Report prepared for Health Canada Workshop, 22 March 2005.
41. Rose N (2005b) Psycho-pharmaceuticals in Europe. In: Knapp M, McDaid D, Mossialos E et al (eds) Mental health policy and practice across Europe. Buckingham: Open University Press.
42. Roses AD (2000) Pharmacogenomics and the practice of medicine. Nature 405 857-865.
43. Smart A, Martin P, Parker M (2004) Tailored medicine: whom will it fit? ethics of patient and disease stratification. Bioethics 18 322-343.
44. Solomon A (2002) The noonday demon: an anatomy of depression. London: Vintage Books.
45. Washington Post (2004) Antidepressant use by US adults soars: cost and risk questions mount in face of overall surge in prescription drugs. 3 December. Available at: http://www.washingtonpost.com (accessed 9 June 2005).
46. World Health Organization (2001) World health report 2001. Geneva: World Health Organization.